Skip to main content
Signal8
Launch Terminal

Finch Therapeutics Group, Inc. (FNCHQ)

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Finch Therapeutics Group, Inc. logo

Finch Therapeutics Group, Inc.

OTC:FNCHQHealthcare
Mkt Cap$16.62M
Float759K
O/S1.61M
Inst Own-
SI0.1%
Dilution
Finch Therapeutics Group, Inc. logoOTC:FNCHQ
FormDescription
15-12G
SEC Filing
EFFECT
POS AM,0001193125-24-249236,2024-11-04
POS AM
Post-Effective Amendment
S-8 POS
SEC Filing
S-8 POS
SEC Filing
S-8 POS
SEC Filing
25
SEC Filing
8-K
3.01,7.01,9.01
10-Q
Quarterly Report
8-K
8.01
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
8-K
3.01
8-K
3.01
10-Q
Quarterly Report
10-K/A
Annual Report (Amended)
8-K
3.01
4
Statement of Changes in Beneficial Ownership
144
Notice of Proposed Sale of Securities
10-K
Annual Report
8-K
3.01,8.01
13G
SCHEDULE 13G
4
Statement of Changes in Beneficial Ownership
144
Notice of Proposed Sale of Securities
8-K
3.01

1-25 of 173

…